Welcome to the Pfizer Securities Litigation Settlement Website
This website provides important information concerning the Settlement of the class action lawsuit brought on behalf of all persons and entities who purchased and/or otherwise acquired Pfizer Inc. ("Pfizer" or "PFE") common stock between and including October 31, 2000 and October 19, 2005.
This class action lawsuit was brought by investors alleging, among other things, that Defendants violated the federal securities laws by making false, misleading or incomplete statements regarding the cardiovascular risks of Celebrex and Bextra. Defendants vigorously denied and disputed Plaintiffs’ claims.
On September 16, 2016, the Court in charge of the In re Pfizer Inc. Securities Litigation preliminarily approved the Settlement, authorized the Settlement Notice to be disseminated to potential Class Members, and scheduled the Final Approval Hearing to consider whether to grant approval to the Settlement.
Subject to Court approval, the Settlement will result in the creation of a cash settlement fund in the principal amount of $486,000,000, plus any interest that may accrue thereon (the “Settlement Fund”). A portion of the Settlement Fund will be used to pay for, among other things, the expense of class notice and administration of the Settlement, taxes and tax-related expenses, Court-awarded attorneys’ fees and expenses to Plaintiffs’ Counsel and Court-awarded reimbursement of costs and expenses to Plaintiffs. The balance of the Settlement Fund will be available for distribution to Class Members who submit valid and timely Claim Forms, according to a Court-approved plan of allocation.
Please be advised that your rights will be affected if you purchased and/or otherwise acquired Pfizer Inc. common stock between and including October 31, 2000 and October 19, 2005.
Please be sure to read the Settlement Notice to fully understand your rights.